Keybank National Association OH bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 2,924 shares of the medical research company’s stock, valued at approximately $316,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. YorkBridge Wealth Partners LLC raised its position in shares of Charles River Laboratories International by 445.5% in the third quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock valued at $118,000 after buying an additional 891 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Charles River Laboratories International by 12.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock valued at $181,000 after buying an additional 202 shares during the last quarter. Riverhead Capital Management LLC increased its position in Charles River Laboratories International by 14.7% during the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after purchasing an additional 247 shares during the last quarter. Cambridge Advisors Inc. acquired a new stake in Charles River Laboratories International during the second quarter worth about $202,000. Finally, Advisor Partners LLC acquired a new stake in Charles River Laboratories International during the second quarter worth about $208,000. Institutional investors and hedge funds own 97.46% of the company’s stock.

Charles River Laboratories International, Inc. (NYSE:CRL) opened at $101.39 on Friday. The company has a quick ratio of 1.62, a current ratio of 1.88 and a debt-to-equity ratio of 1.13. Charles River Laboratories International, Inc. has a 12 month low of $69.51 and a 12 month high of $119.05. The company has a market cap of $4,802.03, a P/E ratio of 19.92, a PEG ratio of 1.62 and a beta of 0.94.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Thursday, November 9th. The medical research company reported $1.30 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.22 by $0.08. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. The business had revenue of $464.23 million during the quarter, compared to analyst estimates of $458.93 million. During the same quarter last year, the firm posted $1.18 earnings per share. The business’s revenue for the quarter was up 9.0% compared to the same quarter last year. sell-side analysts expect that Charles River Laboratories International, Inc. will post 5.13 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was first posted by Daily Political and is the property of of Daily Political. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.dailypolitical.com/2017/11/19/2924-shares-in-charles-river-laboratories-international-inc-crl-purchased-by-keybank-national-association-oh.html.

CRL has been the subject of several recent analyst reports. Zacks Investment Research cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Robert W. Baird restated a “buy” rating and set a $114.00 price objective on shares of Charles River Laboratories International in a research report on Friday, September 1st. BidaskClub cut shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Royal Bank Of Canada initiated coverage on shares of Charles River Laboratories International in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 price objective for the company. Finally, Credit Suisse Group restated a “neutral” rating and set a $112.00 price objective (up from $95.00) on shares of Charles River Laboratories International in a research report on Monday, October 16th. Seven investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $106.63.

In related news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $0.27, for a total value of $270,000.00. Also, insider Davide Molho sold 6,165 shares of the firm’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $110.00, for a total transaction of $678,150.00. The disclosure for this sale can be found here. In the last three months, insiders bought 10,500 shares of company stock valued at $2,885 and sold 1,012,147 shares valued at $1,591,514. Company insiders own 2.20% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.